M Taj1, M Nadeem2, S Maqsood3, T Shah1, T Farzana1, T S Shamsi1. 1. Department of Clinical Hematology and Bone Marrow Transplantation, National Institute of Blood Disease and Bone Marrow Transplantation, ST 2/A Block 17 Gulshan e Iqbal, Sir Shah Suleman Road, KDA Scheme 24, Karachi, Pakistan. 2. Head of Clinical Laboratories, National Institute of Blood Disease and Bone Marrow Transplantation, ST 2/A Block 17 Gulshan e Iqbal, Sir Shah Suleman Road, KDA Scheme 24, Karachi, Pakistan. 3. Department of Research and Development, National Institute of Blood Disease and Bone Marrow Transplantation, ST 2/A Block 17 Gulshan e Iqbal, Sir Shah Suleman Road, KDA Scheme 24, Karachi, Pakistan.
Abstract
OBJECTIVES: The purpose of this study is to evaluate the association of MASCC score (Multinational Association for Supportive Care in Cancer Score) in patients with febrile neutropenia (as resultant treatment of hematological disorders) for risk assessment of morbidity and mortality. PATIENTS AND METHODS: Patients presenting with Febrile Neutropenia from November 2011 till December 2013 were enrolled in the study. Initially all patients were hospitalized and their MASCC score was calculated, however those with high risk stayed in hospital till full ANC recovery while low risk group was discharged earlier and keenly followed as out-patient while being on prophylactic oral antibiotics. The MASCC risk-index score was calculated and patients with risk score >21 were regarded as low-risk while <21 were labeled as high-risk. RESULTS: On the basis of 226 febrile neutropenia patient 132(58.4 %) were categorized as low risk while 94(41.5 %) as high risk patients according to MASCC risk index score. In low risk group 123(93 %) had uncomplicated infection while 9(7 %) had complicated infections. There was no mortality documented in low risk group while eight patients died in high risk group. CONCLUSION: In this study we correctly predicted outcome of 123(93 %) low risk group patients. The study had positive predictive value of 93 % with both sensitivity and specificity of 65 and 75 % respectively. The MASCC risk score is a valuable tool in determining the outcome in patients with febrile neutropenia.
OBJECTIVES: The purpose of this study is to evaluate the association of MASCC score (Multinational Association for Supportive Care in Cancer Score) in patients with febrile neutropenia (as resultant treatment of hematological disorders) for risk assessment of morbidity and mortality. PATIENTS AND METHODS: Patients presenting with Febrile Neutropenia from November 2011 till December 2013 were enrolled in the study. Initially all patients were hospitalized and their MASCC score was calculated, however those with high risk stayed in hospital till full ANC recovery while low risk group was discharged earlier and keenly followed as out-patient while being on prophylactic oral antibiotics. The MASCC risk-index score was calculated and patients with risk score >21 were regarded as low-risk while <21 were labeled as high-risk. RESULTS: On the basis of 226 febrile neutropeniapatient 132(58.4 %) were categorized as low risk while 94(41.5 %) as high risk patients according to MASCC risk index score. In low risk group 123(93 %) had uncomplicated infection while 9(7 %) had complicated infections. There was no mortality documented in low risk group while eight patients died in high risk group. CONCLUSION: In this study we correctly predicted outcome of 123(93 %) low risk group patients. The study had positive predictive value of 93 % with both sensitivity and specificity of 65 and 75 % respectively. The MASCC risk score is a valuable tool in determining the outcome in patients with febrile neutropenia.
Authors: Brahm H Segal; Alison G Freifeld; Lindsey Robert Baden; Arthur E Brown; Corey Casper; Erik Dubberke; Michael Gelfand; John N Greene; Michael G Ison; James I Ito; Judith E Karp; Daniel R Kaul; Earl King; Emily Mackler; Guido Marcucci; Jose G Montoya; Ashley Morris Engemann; Ken Rolston; Angelina S The Journal: J Natl Compr Canc Netw Date: 2008-02 Impact factor: 11.908
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-01-04 Impact factor: 9.079
Authors: J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: Luciano de Souza Viana; José Carlos Serufo; Manoel Otávio da Costa Rocha; Renato Nogueira Costa; Roberto Carlos Duarte Journal: Support Care Cancer Date: 2007-10-25 Impact factor: 3.603
Authors: M Moreau; J Klastersky; A Schwarzbold; F Muanza; A Georgala; M Aoun; A Loizidou; M Barette; S Costantini; M Delmelle; L Dubreucq; M Vekemans; A Ferrant; D Bron; M Paesmans Journal: Ann Oncol Date: 2009-01-12 Impact factor: 32.976
Authors: Frank Daniel Martos-Benítez; Caridad de Dios Soler-Morejón; Karla Ximena Lara-Ponce; Versis Orama-Requejo; Dailé Burgos-Aragüez; Hilev Larrondo-Muguercia; Rahim W Lespoir Journal: World J Clin Oncol Date: 2020-10-24